SCHEMBL5806540

SCHEMBL5806540

COc1ccc(CSc2nc3ccc(S(=O)(=O)N[C@@H](C(=O)NO)C(C)C)cc3s2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 4/20 0.54
MMP2 P08253 3/20 0.54
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 3/20 0.52
LMNA P02545 3/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
THRB P10828 1/20 0.49
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 1/20 0.46
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
MMP1 P03956 2/20 0.45
MMP13 P45452 2/20 0.45
MMP3 P08254 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757635 0.91 MAPT (0.53) MMP9MMP2ALDH1A1GAAMAPT
SCHEMBL5756325 0.90 HTT (0.55) ALDH1A1GAATHRBHPGDTSHR
SCHEMBL5756019 0.90 MAPT (0.53) MMP9MMP2ALDH1A1GAAMAPT
SCHEMBL5755974 0.85 ALDH1A1 (0.55) MMP9MMP2ALDH1A1GAAHPGD
SCHEMBL5754967 0.83 ALDH1A1 (0.53) MMP9MMP2ALDH1A1GAAHPGD
SCHEMBL5755034 0.82 ALDH1A1 (0.55) ALDH1A1GAALMNAHPGDTSHR
SCHEMBL5755760 0.81 ALDH1A1 (0.51) MMP9MMP2ALDH1A1GAAHPGD
SCHEMBL5758844 0.81 MAPT (0.56) ALDH1A1GAAMAPTLMNATHRB
SCHEMBL5759425 0.81 ALDH1A1 (0.51) MMP9MMP2ALDH1A1GAAHPGD
SCHEMBL5754134 0.81 HTT (0.52) MMP9MMP2ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP9 1/4885MMP2 8/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.